Pharma Sector Can Spend Big on M&A -- Market Talk

Dow Jones01-12

1450 GMT - Big pharmaceutical companies could have nearly half a trillion dollars in available cash to spend on mergers and acquisitions through to 2030, according to analysts at Berenberg. In 2026 alone, big pharma companies have an estimated $55 billion of cash available for dealmaking, and Berenberg forecasts at $470 billion their unallocated cash generation in the period through 2030, the analysts say. "Companies with the most cash at their disposal for deals are Eli Lilly, Merck & Co, Roche and AbbVie," they add. Pharma dealmaking was slow last year due to political uncertainty, but there was an acceleration toward the end of the year, Berenberg says. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

January 12, 2026 09:50 ET (14:50 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment